Cempra

Morgan Stanley's Andrew Berens downgraded shares of Cempra Inc (NASDAQ: CEMP) to Underweight from Overweight with a price target slashed to $5 from $35 following the U.S. Food and Drug Administration's vote. The FDA's Antimicrobial Disease Advisory Committee voted in favor of Cempra...

The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...